Last reviewed · How we verify

Hypercalcemia Treatment Adjunct — Treatment Landscape & Competitive Intelligence

Hypercalcemia Treatment Adjunct (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Hypercalcemia Treatment Adjunct, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Osteobios CALCITONIN Sanofi Aventis Us Calcitonin [EPC] calcitonin receptor 2025-01-01
Miacalcin calcitonin (salmon synthetic) Sanofi Calcitonin [EPC] calcitonin receptors 1978-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. · 1 drug in Hypercalcemia Treatment Adjunct
  2. Sanofi · 1 drug in Hypercalcemia Treatment Adjunct
  3. Sanofi Aventis Us · 1 drug in Hypercalcemia Treatment Adjunct

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Hypercalcemia Treatment Adjunct:

Cite this brief

Drug Landscape (2026). Hypercalcemia Treatment Adjunct — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/hypercalcemia-treatment-adjunct. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing